DrugPatentWatch Database Preview
BEPREVE Drug Profile
When do Bepreve patents expire, and when can generic versions of Bepreve launch?
Bepreve is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has forty-five patent family members in sixteen countries.
The generic ingredient in BEPREVE is bepotastine besilate. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bepotastine besilate profile page.
Summary for BEPREVE
| International Patents: | 45 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 62 |
| Clinical Trials: | 5 |
| Patent Applications: | 15 |
| Drug Prices: | Drug price information for BEPREVE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BEPREVE |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for BEPREVE |
| DailyMed Link: | BEPREVE at DailyMed |
Pharmacology for BEPREVE
| Drug Class | Histamine-1 Receptor Antagonist |
Synonyms for BEPREVE
| (+)-(S)-4-(4-((4-Chlorophenyl)(2-pyridyl)methoxy)piperidino)butyric acid monobenzenesulfonate |
| (+)-(S)-4-[4-[1-(4-Chlorophenyl)-1-(2-pyridyl)methoxy]piperidin-1-yl]butyric acid benzenesulfonate |
| (S)-4-(4-((4-chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid compound with benzenesulfonic acid (1:1) |
| (S)-4-[4-(4-Chlorophenyl-2-pyridylmethoxy)piperidinyl]butyric Acid Benzenesulfonate |
| (s)-4-[4-[(4-chlorophenyl)(2-pyridyl)-methoxy]piperidino]butanoic acid monobenzenesulfonic acid salt |
| (s)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid monobenzenesulfonic acid salt |
| 1-Piperidinebutanoic acid, 4-((4-chlorophenyl)-2-pyridinylmethoxy)- (S)-, monobenzenesulfonate |
| 1-piperidinebutanoic acid, 4-[(4-chlorophenyl)-2-pyridinylmethoxy]-, (s)-, monobenzenesulfonate |
| 1-piperidinebutanoic acid, 4-[(s)-(4-chlorophenyl)-2-pyridinylmethoxy]-, monobenzenesulfonate |
| 190786-44-8 |
| 4-((4-Chlorophenyl)-2-pyridinylmethoxy)- (S)-1-piperidinebutanoic acid monobenzenesulfonate |
| 4-[(S)-(4-Chlorophenyl)-2-pyridinylmethoxy]-1-piperidinebutanoic Acid Benzenesulfonate |
| 4-[4-[(r)-(4-chlorophenyl)-pyridin-2-yl-methoxy]-1-piperidyl]butanoic acid |
| 4-{4-[(s)-(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid benzenesulfonate |
| 6W18MO1QR3 |
| 786B448 |
| ABP001064 |
| AC-24015 |
| AC1L4UXJ |
| AC1Q6WSY |
| AK322015 |
| AKOS025401655 |
| AN-5247 |
| API0001668 |
| AS-17863 |
| BC214879 |
| benzenesulfonic acid; 4-[4-[(S)-(4-chlorophenyl)-(2-pyridyl)methoxy]-1-piperidyl]butanoic acid |
| benzenesulfonic acid; 4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid |
| benzenesulfonic acid;4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid |
| Bepomax |
| Bepotastine (Beslilate) |
| Bepotastine benzenesulfonate |
| Bepotastine Benzenesulfonate Salt |
| Bepotastine besilate |
| Bepotastine besilate (JP17) |
| Bepotastine Besitate |
| Bepotastine Beslilat |
| Bepotastine besylate |
| Bepotastine besylate (USAN) |
| Bepotastine besylate [USAN] |
| Bepreve (TN) |
| Betotastine besilate |
| C27H31ClN2O6S |
| CB0259 |
| CHEBI:31281 |
| CHEMBL1201759 |
| CS-0383 |
| CTK4E0497 |
| D01654 |
| DTXSID80172577 |
| FT-0655883 |
| HY-A0015 |
| J-012325 |
| KS-00000FR0 |
| LS-114358 |
| MolPort-005-938-034 |
| PubChem19122 |
| s3037 |
| SB17505 |
| SC-47417 |
| SCHEMBL1287638 |
| SW220161-1 |
| Talion |
| Talion (TN) |
| Tau 284 |
| TAU-284 |
| tau284 |
| UDGHXQPQKQPSBB-BOXHHOBZSA-N |
| UNII-6W18MO1QR3 |
| V2224 |
| W-5279 |
US Patents and Regulatory Information for BEPREVE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | AT | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | AT | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | |
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | AT | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for BEPREVE
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | ➤ Try a Free Trial |
International Patents for BEPREVE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5518928 | ➤ Try a Free Trial |
| Japan | 2014169294 | ➤ Try a Free Trial |
| Austria | 528003 | ➤ Try a Free Trial |
| Spain | 2173499 | ➤ Try a Free Trial |
| Country | Patent Number | Estimated Expiration |
